Ask Bio, acquired by Bayer for more than $2 billion in 2020, is enrolling patients for a new clinical trial focused on the therapy's effectiveness in adult patients with non-ischemic cardiomyopathy and heart failure. 

The practice's mobile MR unit imaged nearly 2,400 patients in 2022, and leaders are projecting 94% growth by next year. 

Leaders said previously that the publicly traded imaging provider will use the proceeds to fuel growth in Houston and elsewhere.